A phase 3 trial of the mTor inhibitor everolimus demonstrated no survival benefit for patients with advanced HCC who had failed sorafenib; however, the participants were not selected by PTEN or other PI3K-related abnormalities. This evidence concerns the gene PTEN and hepatocellular carcinoma.